logo-loader
viewBrainStorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics looks forward to top-line results for its ALS Phase 3 program

BrainStorm Cell Therapeutics (NASDAQ:BCLI) COO and Chief Medical Officer Ralph Kern sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The biotech is focused on generating top-line results for its ALS Phase 3 and progressive MS Phase 2 trials in Q4 2020 to gain eventual commercialization of its therapy called NurOwn in ALS.

Quick facts: BrainStorm Cell Therapeutics Inc.

Price: 4.35 USD

NASDAQ:BCLI
Market: NASDAQ
Market Cap: $98.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

1 day, 6 hours ago

2 min read